Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)
Condition: Other Cancer Intervention: Drug: ruxolitinib Sponsors: Massachusetts General Hospital; Incyte Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials